JP2024527401A5 - - Google Patents

Info

Publication number
JP2024527401A5
JP2024527401A5 JP2024501831A JP2024501831A JP2024527401A5 JP 2024527401 A5 JP2024527401 A5 JP 2024527401A5 JP 2024501831 A JP2024501831 A JP 2024501831A JP 2024501831 A JP2024501831 A JP 2024501831A JP 2024527401 A5 JP2024527401 A5 JP 2024527401A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
composition according
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527401A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/105077 external-priority patent/WO2023284710A1/en
Publication of JP2024527401A publication Critical patent/JP2024527401A/ja
Publication of JP2024527401A5 publication Critical patent/JP2024527401A5/ja
Pending legal-status Critical Current

Links

JP2024501831A 2021-07-13 2022-07-12 神経学的疾患を処置する方法 Pending JP2024527401A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221261P 2021-07-13 2021-07-13
US63/221,261 2021-07-13
PCT/CN2022/105077 WO2023284710A1 (en) 2021-07-13 2022-07-12 Methods of treating neurological diseases

Publications (2)

Publication Number Publication Date
JP2024527401A JP2024527401A (ja) 2024-07-24
JP2024527401A5 true JP2024527401A5 (https=) 2025-07-22

Family

ID=84919904

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501831A Pending JP2024527401A (ja) 2021-07-13 2022-07-12 神経学的疾患を処置する方法

Country Status (10)

Country Link
US (1) US20240309089A1 (https=)
EP (1) EP4370153A4 (https=)
JP (1) JP2024527401A (https=)
KR (1) KR20240042443A (https=)
CN (1) CN117999096A (https=)
AU (1) AU2022310081A1 (https=)
CA (1) CA3225077A1 (https=)
MX (1) MX2024000591A (https=)
WO (1) WO2023284710A1 (https=)
ZA (1) ZA202400405B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3710471A1 (en) * 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
WO2024197258A1 (en) * 2023-03-23 2024-09-26 Klaritos, Inc Methods of treating alzheimer's disease
WO2025190311A1 (en) * 2024-03-12 2025-09-18 Sinomab Bioscience Limited Method of identifying anti-siglec antibodies possessing cis-trans converter properties, anti-siglec antibodies and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US9066928B1 (en) * 2012-12-04 2015-06-30 University Of Kentucky Research Foundation Method, composition, and kit useful for treatment of alzheimer's disease
AU2014305658A1 (en) * 2013-08-05 2016-02-11 St. Vincent's Institute Of Medical Research An antibody therapy for amyloid beta disease
WO2017196432A1 (en) * 2016-05-12 2017-11-16 La Jolla Institute For Allergy And Immunology Compositions and methods for diagnosing and treating neurodegenerative disease
EP3867280A4 (en) * 2018-10-18 2022-11-09 Sinomab Bioscience Limited METHODS OF TREATMENT OF RHEUMATOID ARTHRITIS
ES2821599A1 (es) * 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer

Similar Documents

Publication Publication Date Title
JP2024527401A5 (https=)
KR102757960B1 (ko) 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
TWI306458B (en) Humanized antibodies that recognize beta amyloid peptide
JP2021191763A5 (https=)
JP2006522830A5 (https=)
JP2018502558A5 (https=)
JP2019527194A5 (https=)
CA2478049A1 (en) Humanized antibodies that recognize beta amyloid peptide
JP2023541860A5 (https=)
CA2494008A1 (en) Anti-myelin associated glycoprotein (mag) antibodies
JP2019505527A5 (https=)
JP2009530423A5 (https=)
JP2023542290A5 (https=)
JP2013508292A5 (https=)
JP2021511387A5 (https=)
JP2021525806A5 (https=)
JP2019517540A5 (https=)
JP2020527152A5 (https=)
JP2023516441A5 (https=)
JP2023548064A5 (https=)
JP2022542472A5 (https=)
JP2022500382A5 (https=)
JP2023546504A5 (https=)
JP2025130076A5 (https=)
US20240417451A1 (en) Therapeutic Use of Bispecific Anti-Abeta/TfR Antibodies